[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30.
https://doi.org/10.3322/caac.21442
|
[2]
|
Ferlay, J., Soerjomataram, I., Dikshit, R., et al. (2015) Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359-E386.
https://doi.org/10.1002/ijc.29210
|
[3]
|
Bosetti, C., Lucenteforte, E., Silverman, D.T., et al. (2012) Cigar and Pipe Smoking, Smokeless Tobacco Use and Pancreatic Cancer: An Analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Annals of Oncology, 23, 1880-1888. https://doi.org/10.1093/annonc/mds491
|
[4]
|
Michaud, D.S., Giovannucci, E., Willett, W.C., et al. (2001) Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer. JAMA, 286, 921-929. https://doi.org/10.1001/jama.286.8.921
|
[5]
|
Gapstur, S.M., Jacobs, E.J., Deka, A., et al. (2011) Association of Alcohol Intake with Pancreatic Cancer Mortality in Never Smokers. Archives of Internal Medicine, 171, 444-451. https://doi.org/10.1001/archinternmed.2010.536
|
[6]
|
Bansal, P. and Sonnenberg, A. (1995) Pancreatitis Is a Risk Factor for Pancreatic Cancer. Gastroenterology, 109, 247-251. https://doi.org/10.1016/0016-5085(95)90291-0
|
[7]
|
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., et al. (2005) Type-II Diabetes and Pancreatic Cancer: A Meta-Analysis of 36 Studies. British Journal of Cancer, 92, 2076-2083. https://doi.org/10.1038/sj.bjc.6602619
|
[8]
|
Giovannucci, E., Harlan, D.M., Archer, M.C., et al. (2010) Diabetes and Cancer: A Consensus Report. CA: A Cancer Journal for Clinicians, 60, 207-221. https://doi.org/10.3322/caac.20078
|
[9]
|
Permuth Wey, J. and Egan, K.M. (2009) Family History Is a Significant Risk Factor for Pancreatic Cancer: Results from a Systematic Review and Meta-Analysis. Familial Cancer, 8, 109-117.
https://doi.org/10.1007/s10689-008-9214-8
|
[10]
|
Fan, X., Alekseyenko, A.V., Wu, J., et al. (2018) Human Oral Microbiome and Prospective Risk for Pancreatic Cancer: A Population-Based Nested Case-Control Study. Gut, 67, 120-127. https://doi.org/10.1136/gutjnl-2016-312580
|
[11]
|
于文滨. 60例胰十二指肠切除手术治疗胰腺癌临床分析[J]. 中国现代药物应用, 2013, 7(5): 49-50.
|
[12]
|
Ishikawa, O., Ohhigashi, H., Sasaki, Y., et al. (1988) Practical Usefulness of Lymphatic and Connective Tissue Clearance for the Carcinoma of the Pancreas Head. Annals of Surgery, 208, 215-220.
https://doi.org/10.1097/00000658-198808000-00014
|
[13]
|
Reddy, S.K., Tyler, D.S., Pappas, T.N., et al. (2007) Extended Resection for Pancreatic Adenocarcinoma. Oncologist, 12, 654-663. https://doi.org/10.1634/theoncologist.12-6-654
|
[14]
|
Pedrazzoli, S. (2015) Extent of Lymphadenectomy to Associate with Pancreaticoduodenectomy in Patients with Pancreatic Head Cancer for Better Tumor Staging. Cancer Treatment Reviews, 41, 577-587.
https://doi.org/10.1016/j.ctrv.2015.04.013
|
[15]
|
Zhou, M., Cui, J.J., Wang, L.W., et al. (2017) Selection and Therapeutic Effect Evaluation of Chemotherapy Regimens for Pancreatic Cancer. Journal of Clinical Hepatology, 33, 53-56.
|
[16]
|
Wiggans, R.G., Woolley, P.V., Macdonald, J.S., et al. (1978) Phase II Trial of Streptozotocin, Mitomycin-C and 5-Fluorouracil (SMF) in the Treatment of Advanced Pancreatic Cancer. Cancer, 41, 387-391.
https://doi.org/10.1002/1097-0142(197802)41:2<387::AID-CNCR2820410201>3.0.CO;2-X
|
[17]
|
Carmichael, J. (1997) Clinical Response Benefit in Patients with Advanced Pancreatic Cancer. Role of Gemcitabine. Digestion, 58, 503-507. https://doi.org/10.1159/000201493
|
[18]
|
郭双双, 王羽, 杨琼, 等. 吉西他滨联合5-FU或卡培他滨与吉西他滨单药治疗晚期胰腺癌对比的Meta分析[J]. 循证医学, 2006, 6(1): 42-47.
|
[19]
|
Novarino, A., Chiappino, I., Bertelli, G.F., et al. (2004) Phase II Study of Cisplatin, Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer. Annals of Oncology, 15, 474-477. https://doi.org/10.1093/annonc/mdh106
|
[20]
|
Loehrer, P.J., Feng, Y., Cardenes, H., et al. (2011) Gemcitabine Alone versus Gemcitabine plus Radiotherapy in Patients with Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 29, 4105-4112. https://doi.org/10.1200/JCO.2011.34.8904
|
[21]
|
Ng, S.P. and Herman, J.M. (2018) Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer. Cancers (Basel), 10, pii: E75. https://doi.org/10.3390/cancers10030075
|
[22]
|
Schellenberg, D., Goodman, K.A., Lee, F., et al. (2008) Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. In-ternational Journal of Radiation Oncology, Biology, Physics, 72, 678-686. https://doi.org/10.1016/j.ijrobp.2008.01.051
|
[23]
|
Mulvihill, S., Warren, R., Venook, A., et al. (2001) Safety and Feasibility of Injection with an E1B-55 kDa Gene-Deleted, Replication-Selective Adenovirus (ONYX-015) into Primary Carcinomas of the Pancreas: A Phase I Trial. Gene Therapy, 8, 308-315. https://doi.org/10.1038/sj.gt.3301398
|
[24]
|
Duda, D.G., Sunamura, M. and Lefter, L.P. (2003) Restoration of SMAD4 by Gene Therapy Reverses the Invasive Phenotype in Pancreatic Adenocarcinoma Cells. Oncogene, 22, 6857-6864. https://doi.org/10.1038/sj.onc.1206751
|
[25]
|
Xue, W., Chen, S.D., Yin, H., et al. (2014) CRISPR-Mediated Direct Mutation of Cancer Genes in the Mouse Live. Nature, 514, 380-384. https://doi.org/10.1038/nature13589
|
[26]
|
van Dyke, T. and Jacks, T. (2002) Cancer Modeling in the Modern Era: Progress and Challenges. Cell, 108, 135-144.
https://doi.org/10.1016/S0092-8674(02)00621-9
|
[27]
|
Jaffee, E.M., Hruban, R.H., Biedrzycki, B., et al. (2001) Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation. Journal of Clinical Oncology, 19, 145-156. https://doi.org/10.1200/JCO.2001.19.1.145
|
[28]
|
Bernhardt, S.L., Gjertsen, M.K., Trachsel, S., et al. (2006) Te-lomerase Peptide Vaccination of Patients with Non-Resectable Pancreatic Cancer: A Dose Escalating Phase I/II Study. British Journal of Cancer, 95, 1474-1482.
https://doi.org/10.1038/sj.bjc.6603437
|
[29]
|
Copper, I.S. (1963) Cryogenic Surgery: A New Method of Destruction or Extirpation of Benign or Malignant Tissues. The New England Journal of Medicine, 268, 743-749. https://doi.org/10.1056/NEJM196304042681401
|
[30]
|
Clarke, D.M., Baust, J.M., Van Buskirk, R.G., et al. (2004) Addition of Anticancer Agents Enhances Freezing-Induced Prostate Cancer Cell Death: Implications of Mitochondrial Involvement. Cryobiology, 49, 45-61.
https://doi.org/10.1016/j.cryobiol.2004.05.003
|
[31]
|
李波, 李敬东, 陈晓理, 等. 无法切除的胰腺癌的冷冻手术治疗(附44例报告) [J]. 中华肝胆外科杂志, 2004, 10(8): 523-525.
|
[32]
|
Kovach, S.J., Hendrickson, R.J., Cappadona, C.R., et al. (2002) Cryoablation of Unresectable Pancreatic Cancer Surgery. Surgery, 131, 463-464. https://doi.org/10.1067/msy.2002.121231
|
[33]
|
Ma, Y., Zou, F., Xiong, J., et al. (2015) Effect of Matrine on HPAC Cell Migration by Down-Regulating the Expression of MT1-MMP via Wnt Signaling. Cancer Cell International, 15, 59. https://doi.org/10.1186/s12935-015-0210-4
|
[34]
|
Singh, K., Dong, Q., Shanmugam, T., et al. (2018) Tetrandrine Inhibits Deregulated Cell Cycle in Pancreatic Cancer Cells: Differential Regulation of p21Cip1/Waf1, p27Kip1 and Cyclin D1. Cancer Letters, 425, 164-173.
https://doi.org/10.1016/j.canlet.2018.03.042
|
[35]
|
Von Hoff, D.D., Ervin, T., Arena, F.P., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. The New England Journal of Medicine, 369, 1691-1703. https://doi.org/10.1056/NEJMoa1304369
|
[36]
|
谢铮铮, 梁瑶, 孙路路. 厄洛替尼联合吉西他滨治疗胰腺癌有效性和安全性的Meta分析[J]. 中国临床药理学杂志, 2016, 32(8): 746-748.
|
[37]
|
Moore, M.J., Goldstein, D., Hamm, J., et al. (2007) Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1960-1966. https://doi.org/10.1200/JCO.2006.07.9525
|